UBS downgraded Alkermes to Sell from Neutral with an unchanged price target of $25. The shares are trading close to their 52-week high and there is a negative risk/reward from pipeline updates and launch performance, the analyst tells investors in a research note. Alkermes’ current valuation is pricing in $2.2B in 2029 sales, versus UBS’s base case of $1.6B, indicating perfection on the orexin clinical outcome and solid Lybalvi growth, contends the firm. UBS is cautious on the orexin Phase 1 read-out during the first half of 2024 expects Lybalvi misses and consensus downward revisions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALKS:
- Alkermes price target raised to $33 from $30 at BofA
- Alkermes price target raised to $39 from $35 at Piper Sandler
- Alkermes price target raised to $35 from $34 at H.C. Wainwright
- Alkermes sees 2024 revenue $1.5B-$1.6B, consensus $1.52B
- Alkermes reports Q4 non-GAAP EPS 22c, consensus 51c
Questions or Comments about the article? Write to editor@tipranks.com